Astrana Health, Inc. quarterly report, Q2 FY2013

Business context and reporting period

This Form 10-Q is for Apollo Medical Holdings, Inc. (the registrant named in the filing), for the three and six months ended July 31, 2012. The request metadata names Astrana Health, Inc.; that name does not appear as the registrant in the provided filing text. Apollo managed hospitalist and pulmonary/critical-care services in California through affiliated physician practices. On July 10, 2012, its ApolloMed ACO was selected to participate in CMS’s Medicare Shared Savings Program.

Financial performance and position

Revenue grew 51% year over year in the quarter and 54% for the six-month period. The gross margin improved from 14.1% to 26.9% in the quarter and from 11.6% to 22.8% for six months. Operating losses narrowed compared with 2011, but net losses widened sharply, primarily because of non-cash fair-value losses on derivative and warrant liabilities: $2.915 million in the quarter and $2.791 million for six months. Six-month interest and financing costs were $449,000, versus $82,000 a year earlier.

At July 31, cash was $259,000, current assets $1.352 million, and current liabilities $4.471 million. Total liabilities were $5.076 million; stockholders’ deficit was $3.608 million. Debt principal was $1.670 million: $270,000 of secured notes, $1.250 million of 10% convertible notes, and $150,000 of 8% convertible notes. After a $327,000 debt discount, reported net debt was $1.343 million. The filing reports $170,000 net cash from financing during the six months, including $270,000 of note proceeds and a $100,000 distribution to a non-controlling shareholder.

Material changes versus the prior comparable period

• Quarterly revenue rose by about $556,000; management attributed growth to the LALC acquisition and expanded fee-for-service work at new and existing hospital clients. The six-month increase was about $1.148 million.
• Cost of services fell as a share of revenue, while general and administrative expense increased to $502,000 for the quarter and $853,000 for six months, reflecting growth-related costs, in-house billing, executive role reallocation, acquisition costs, and non-cash stock compensation.
• Operating losses improved, but fair-value remeasurement of financing-related liabilities and higher interest expense drove substantially larger net losses.
• Cash increased by $95,000 from January 31, 2012. The balance sheet shifted to a larger current-liability position, including a new $270,000 secured note and sharply higher derivative and warrant liabilities.

Outlook, risks, contingencies, and unusual items

• Going concern: Management stated that losses could continue through fiscal 2013 and that available liquidity might not sustain operations for the next 12 months, raising substantial doubt about the company’s ability to continue as a going concern. Management planned to seek additional capital; success was not assured, and failure to raise funds could force cessation of operations.
• Debt maturities: The $270,000 secured note was due in two $135,000 installments on September 15 and October 15, 2012. The $1.250 million 10% convertible notes mature January 31, 2013. Management identified $1.520 million of fiscal 2013 debt maturities.
• ACO initiative: Management viewed MSSP participation as a growth opportunity, with potential shared savings subject to quality and savings performance, but said additional capital would be needed.
• Controls: Disclosure controls and internal controls over financial reporting were deemed ineffective as of July 31, 2012. The filing identified material weaknesses in documented control procedures, segregation of duties, and financial reporting review and supervision; remediation was underway.
• Concentrations and legal matters: Three customers represented 47.5% of quarterly revenue and 46.4% of six-month revenue. The company reported ordinary-course legal matters, including medical-malpractice claims; outcomes were uncertain, though management did not expect a material adverse effect based on its review.
• Subsequent transaction: On August 1, 2012, the company agreed to acquire Verdugo Medical Management, Inc. and described related consulting and restricted-share arrangements. The filing states the related medical group would be consolidated beginning on that date.

Important facts for investors to verify

1. Confirm the issuer identity and reporting period: the supplied filing names Apollo Medical Holdings, Inc., not Astrana Health, Inc.
2. Reconcile the quarter’s revenue: the financial statements show $1,649,451, while MD&A states $1,649,651.
3. Assess near-term liquidity against the $1.520 million of stated fiscal 2013 debt maturities and management’s going-concern warning.
4. Review the assumptions and potential cash or dilution consequences associated with the derivative and warrant liabilities and convertible notes.
5. Track whether control weaknesses were remediated and whether customer concentration, ACO funding needs, and the August 2012 acquisition affect results.